Thu. 15 Feb 2024, 4:02pm ET
Benzinga
Earnings, News
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.62) by 6.17 percent. This is a 29.63 percent increase over losses of $(2.16) per share from the same period last year. The company reported quarterly sales of $127.39 million which beat the analyst consensus estimate of $119.38 million by 6.71 percent. This is a 23.27 percent increase over sales of $103.35 million the same period last year.